Summary
This prediction ended on 12.10.15 with a price of €4.04. The BUY prediction by gerihouse finished with a performance of 5.71%. gerihouse has 50% into this predictionEvotec is a German-based biotech company that provides drug discovery and development solutions to pharmaceutical and biotechnology companies. The company operates in the fields of neuroscience, immunology, oncology, and infectious diseases, and its services include hit identification, target validation, and preclinical and clinical development. Evotec has partnerships with major pharmaceutical companies and has developed its own pipeline of drugs, with a focus on developing treatments for conditions such as Alzheimer's disease and diabetes. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of approximately €5.5 billion.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Evotec SE | 4.652% | 4.652% | -41.565% | -71.923% |
| iShares Core DAX® | -0.922% | -1.993% | 13.399% | 16.075% |
| iShares Nasdaq 100 | 0.371% | -0.868% | 41.541% | 46.938% |
| iShares Nikkei 225® | 2.224% | -5.187% | 20.497% | 4.643% |
| iShares S&P 500 | -0.026% | -0.918% | 30.410% | 42.418% |
According to gerihouse what are the pros and cons of Evotec SE for the foreseeable future?
Pros
Cons
Comments by gerihouse for this prediction
In the thread Evotec AG diskutieren
gerihouse stimmt der fundamentalen Bewertung mit dem Ergebnis 'überbewertet' nicht zu
gerihouse stimmt am 10.09.2015 der fundamentalen Bewertung mit dem Ergebnis überbewertet nicht zu.
Erfangt sich wieder!
Das Düsseldorfer Bankhaus Lampe hat die Einstufung für Evotec nach der Bekanntgabe einer Partnerschaft mit Pfizer auf "Kaufen" mit einem Kursziel von 4,60 Euro belassen. Dies sei eine schöne Ergänzung der Pipeline des Biotechnologie-Unternehmens, die mehr als 70 Partnerprojekte umfasse, schrieb Analyst Volker Braun in einer Studie vom Mittwoch
